Abstract
Taxanes (paclitaxel and docetaxel) are among the most active cytotoxic agents in use in oncology, being widely used in adjuvant and advanced treatment settings in multiple tumor types. Due to the impressive benefits offered by the taxanes, different strategies are in development, aimed at reducing their systemic toxicity and the need for premedication, while improving anti-tumor spectra and treatment efficacy. Although a remarkable amount of effort has been aimed at overcoming delivery difficulties, very few compounds have reached clinical trials, and some of those few have failed advanced trials. This mini-review reports the most recent developments in advanced taxane delivery approaches, with particular focus on receptor-targeted delivery systems.
Keywords: Taxanes, conjugates, micelles, nanoparticles, chemotherapy, cancer, drug delivery, cancer cells, EGFR, POLYMERIC MICELLES
Drug Delivery Letters
Title: Targeted Taxane Delivery Systems: Recent Advances
Volume: 1 Issue: 2
Author(s): Daniela Gastaldi, Daniele Zonari and Franco Dosio
Affiliation:
Keywords: Taxanes, conjugates, micelles, nanoparticles, chemotherapy, cancer, drug delivery, cancer cells, EGFR, POLYMERIC MICELLES
Abstract: Taxanes (paclitaxel and docetaxel) are among the most active cytotoxic agents in use in oncology, being widely used in adjuvant and advanced treatment settings in multiple tumor types. Due to the impressive benefits offered by the taxanes, different strategies are in development, aimed at reducing their systemic toxicity and the need for premedication, while improving anti-tumor spectra and treatment efficacy. Although a remarkable amount of effort has been aimed at overcoming delivery difficulties, very few compounds have reached clinical trials, and some of those few have failed advanced trials. This mini-review reports the most recent developments in advanced taxane delivery approaches, with particular focus on receptor-targeted delivery systems.
Export Options
About this article
Cite this article as:
Gastaldi Daniela, Zonari Daniele and Dosio Franco, Targeted Taxane Delivery Systems: Recent Advances, Drug Delivery Letters 2011; 1 (2) . https://dx.doi.org/10.2174/2210304x11101020105
DOI https://dx.doi.org/10.2174/2210304x11101020105 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanoparticle-Based Tumor Theranostics with Molecular Imaging
Current Pharmaceutical Biotechnology Microdosing, Imaging Biomarkers and SPECT: A Multi-Sided Tripod to Accelerate Drug Development
Current Pharmaceutical Design FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Transforming Growth Factor Beta in Pancreatic Cancer
Current Pharmaceutical Biotechnology Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Crude Venom from Nematocysts of the Jellyfish Pelagia noctiluca as a Tool to Study Cell Physiology
Central Nervous System Agents in Medicinal Chemistry Ion Transporters in Brain Tumors
Current Medicinal Chemistry Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Cell Nucleus Directed 2,3,5-triiodobenzoic Acid Conjugates
Medicinal Chemistry Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Graphical Abstracts
Letters in Drug Design & Discovery Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An <i>In Silico</i> Approach
Current Cancer Drug Targets Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Current Drug Metabolism Multimodal Navigation in Glioma Surgery
Current Medical Imaging Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti-Cancer Drug Target
Current Pharmaceutical Biotechnology The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets